NCT00750698View on ClinicalTrials.gov

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

June 30, 2010

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Entinostat

Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles

DRUG

Erlotinib

Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles

Trial Locations (5)

29425

Medical University of South Carolina, Charleston

33136

University of Miami, Miami

60612

Rush University Medical Center, Chicago

92123

Sharp Clinical Oncology Research, San Diego

Unknown

Roswell Park Cancer Institute, Buffalo

Sponsors
All Listed Sponsors
lead

Syndax Pharmaceuticals

INDUSTRY